Direct Costs Associated with Relapsed Diffuse Large B-Cell Lymphoma Therapies
Abstract Background About one third of patients with diffuse large B-cell lymphoma (DLBCL) relapse after receiving first-line (1L) treatment of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Relapsed patients may then be eligible for second-line (2L) therapy. The stu...
Sábháilte in:
| Príomhchruthaitheoirí: | , , , |
|---|---|
| Formáid: | Artigo |
| Teanga: | Béarla |
| Foilsithe / Cruthaithe: |
2019
|
| Rochtain ar líne: | https://doi.org/10.1634/theoncologist.2018-0490 https://theoncologist.onlinelibrary.wiley.com/doi/pdfdirect/10.1634/theoncologist.2018-0490 |
| Clibeanna: |
Cuir clib leis
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!
|